4//SEC Filing
Frazier Life Sciences VIII, L.P. 4
Accession 0001209191-20-007100
CIK 0001787306other
Filed
Feb 5, 7:00 PM ET
Accepted
Feb 6, 10:29 AM ET
Size
21.8 KB
Accession
0001209191-20-007100
Insider Transaction Report
Form 4
FHM LIFE SCIENCES VIII, L.P.
10% Owner
Transactions
- Conversion
Series C Preferred Stock
2020-02-04−1,074,467→ 0 total→ Common Stock (1,074,467 underlying) - Conversion
Common Stock
2020-02-04+2,099,019→ 8,968,323 total - Conversion
Common Stock
2020-02-04+1,074,467→ 10,042,790 total - Purchase
Common Stock
2020-02-04$17.00/sh+500,000$8,500,000→ 10,542,790 total - Conversion
Common Stock
2020-02-04+6,360,272→ 6,869,304 total - Conversion
Series A Preferred Stock
2020-02-04−6,360,272→ 0 total→ Common Stock (6,360,272 underlying) - Conversion
Series B Preferred Stock
2020-02-04−2,099,019→ 0 total→ Common Stock (2,099,019 underlying)
FHM LIFE SCIENCES VIII, L.L.C.
10% Owner
Transactions
- Conversion
Series B Preferred Stock
2020-02-04−2,099,019→ 0 total→ Common Stock (2,099,019 underlying) - Conversion
Common Stock
2020-02-04+6,360,272→ 6,869,304 total - Conversion
Common Stock
2020-02-04+1,074,467→ 10,042,790 total - Purchase
Common Stock
2020-02-04$17.00/sh+500,000$8,500,000→ 10,542,790 total - Conversion
Series C Preferred Stock
2020-02-04−1,074,467→ 0 total→ Common Stock (1,074,467 underlying) - Conversion
Common Stock
2020-02-04+2,099,019→ 8,968,323 total - Conversion
Series A Preferred Stock
2020-02-04−6,360,272→ 0 total→ Common Stock (6,360,272 underlying)
Frazier Life Sciences VIII, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2020-02-04+6,360,272→ 6,869,304 total - Conversion
Common Stock
2020-02-04+2,099,019→ 8,968,323 total - Conversion
Common Stock
2020-02-04+1,074,467→ 10,042,790 total - Purchase
Common Stock
2020-02-04$17.00/sh+500,000$8,500,000→ 10,542,790 total - Conversion
Series A Preferred Stock
2020-02-04−6,360,272→ 0 total→ Common Stock (6,360,272 underlying) - Conversion
Series B Preferred Stock
2020-02-04−2,099,019→ 0 total→ Common Stock (2,099,019 underlying) - Conversion
Series C Preferred Stock
2020-02-04−1,074,467→ 0 total→ Common Stock (1,074,467 underlying)
Topper James N
10% Owner
Transactions
- Conversion
Common Stock
2020-02-04+6,360,272→ 6,869,304 total - Conversion
Common Stock
2020-02-04+2,099,019→ 8,968,323 total - Purchase
Common Stock
2020-02-04$17.00/sh+500,000$8,500,000→ 10,542,790 total - Conversion
Series A Preferred Stock
2020-02-04−6,360,272→ 0 total→ Common Stock (6,360,272 underlying) - Conversion
Series B Preferred Stock
2020-02-04−2,099,019→ 0 total→ Common Stock (2,099,019 underlying) - Conversion
Series C Preferred Stock
2020-02-04−1,074,467→ 0 total→ Common Stock (1,074,467 underlying) - Conversion
Common Stock
2020-02-04+1,074,467→ 10,042,790 total
Footnotes (2)
- [F1]Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.
- [F2]The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any.
Documents
Issuer
Arcutis Biotherapeutics, Inc.
CIK 0001787306
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001655827
Filing Metadata
- Form type
- 4
- Filed
- Feb 5, 7:00 PM ET
- Accepted
- Feb 6, 10:29 AM ET
- Size
- 21.8 KB